ReviewExpert review of neurotherapeutics2012
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
Review in Expert review of neurotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Unraveling the mystery of white matter in depression: A translational perspective on recent advances.Brain and behavior · 2022Pooled it
- Secondary Mania induced by TNF-α inhibitors: A systematic review.Psychiatry and clinical neurosciences · 2022Pooled it
- Association of trauma exposure with proinflammatory activity: a transdiagnostic meta-analysis.Translational psychiatry · 2014Pooled it
- Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.Molecular psychiatry · 2016Trial
- Choroid plexus inflammation in bipolar disorder.Brain, behavior, and immunity · 2026Article
- Blunted niacin skin flushing response with subtype-specific clinical associations in adolescent bipolar disorder.BMC psychiatry · 2026Article
- Immune dysregulation and neuroinflammation in bipolar disorder: Pathophysiological insights and therapeutic perspectives.Brain, behavior, & immunity - health · 2026Review
- Macromolecular Proton Fraction Reveals Divergent White Matter Myelination in Bipolar Disorder and Unipolar Recurrent Depression.Bioengineering (Basel, Switzerland) · 2026Article
- Advances and Challenges in Depression Marker Research.Neuropsychiatric disease and treatment · 2025Review
- Pain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritis.Rheumatology advances in practice · 2025Article
- Understanding immune system dysfunction and its context in mood disorders: psychoneuroimmunoendocrinology and clinical interventions.Military Medical Research · 2024Review
- Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis.BMC psychiatry · 2024Article
- Circulating JKAP levels may correlate with postpartum anxiety and depression through its interaction with T helper 17 cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Microbiota-gut-brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities.Molecular psychiatry · 2023Review
- Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.Frontiers in neuroscience · 2023Review
- Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time.Comprehensive psychoneuroendocrinology · 2022Article
- Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment.American journal of translational research · 2022Article
- Carveol Promotes Nrf2 Contribution in Depressive Disorders through an Anti-inflammatory Mechanism.Oxidative medicine and cellular longevity · 2022Article
- The Microbiota/Microbiome and the Gut-Brain Axis: How Much Do They Matter in Psychiatry?Life (Basel, Switzerland) · 2021Review
- Transcriptomic Deconvolution of Dorsal Striata Reveals Increased Monocyte Fractions in Bipolar Disorder.Complex psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Converging translational evidence has implicated elevated immune-inflammatory signaling activity in the pathoetiology of mood disorders, including major depressive disorder and bipolar disorder. This is supported in part by cross-sectional evidence for increased levels of proinflammatory eicosanoids, cytokines and acute-phase proteins during mood episodes, and prospective longitudinal evidence for the emergence of mood symptoms in response to chronic immune-inflammatory activation. In addition, mood-stabilizer and atypical antipsychotic medications downregulate initial components of the immune-inflammatory signaling pathway, and adjunctive treatment with anti-inflammatory agents augment the therapeutic efficacy of antidepressant, mood stabilizer and atypical antipsychotic medications. Potential pathogenic mechanisms linked with elevated immune-inflammatory signaling include perturbations in central serotonin neurotransmission and progressive white matter pathology. Both heritable genetic factors and environmental factors including dietary fatty-acid composition may act in concert to sustain elevated immune-inflammatory signaling. Collectively, these data suggest that elevated immune-inflammatory signaling is a mechanism that is relevant to the pathoetiology of mood disorders, and may therefore represent a new therapeutic target for the development of more effective treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.